Crump, John A, Nyirenda, Tonney S, Kalonji, Lisette Mbuyi, Phoba, Marie-France, Tack, Bieke, Platts-Mills, James A, Gordon, Melita A 
ORCID: 0000-0002-0629-0884 and Kariuki, Samuel M
(2023)
Nontyphoidal Salmonella Invasive Disease: Challenges and Solutions.
OPEN FORUM INFECTIOUS DISEASES, 10 (Suppl ).
S32-S37.
Abstract
Nontyphoidal <i>Salmonella</i> are a leading cause of community-onset bacteremia and other serious infections in sub-Saharan African countries where large studies indicate that they are an uncommon cause of moderate-to-severe diarrhea. Approximately 535 000 nontyphoidal <i>Salmonella</i> invasive disease illnesses and 77 500 deaths were estimated to occur in 2017; 422 000 (78.9%) illnesses and 66 500 (85.9%) deaths in countries in sub-Saharan Africa. Lineages of <i>Salmonella enterica</i> serovar Typhimurium sequence type (ST) 313 and lineages of <i>Salmonella enterica</i> serovar Enteritidis ST11 dominate as causes of invasive disease. A major reservoir for these specific strains outside of humans has not been identified to date. Human fecal shedding of such strains is common in areas where nontyphoidal <i>Salmonella</i> invasive disease incidence is high. The case-fatality ratio of nontyphoidal <i>Salmonella</i> invasive disease is approximately 15%. Early diagnosis and treatment are needed to avert fatal outcomes. Antimicrobial resistance, including multiple drug resistance, decreased fluoroquinolone susceptibility, and resistance to third-generation cephalosporins, is increasing in prevalence and is likely to further compromise patient outcomes. Naturally acquired immunity against invasive disease develops in children aged >3 years in endemic areas, likely mediated in part by the sequential acquisition of T-cell immunity, followed by antigen-specific immunoglobulin G antibodies. Vaccines in preclinical or clinical development include live-attenuated <i>S. enterica</i> serovar Typhimurium, nontyphoidal <i>S. enterica</i> core and O-polysaccharide glycoconjugates, multiple antigen-presenting system complexes, and generalized modules for membrane antigens vaccines. The latter are in phase I trials in Europe and Africa. Both vaccine use, and other effective, evidence-based nonvaccine interventions, are needed to prevent and control nontyphoidal <i>Salmonella</i> invasive disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | antimicrobial drug resistance, bacteremia, diarrhea, epidemiology, Salmonella, vaccines |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 05 Oct 2023 08:51 |
| Last Modified: | 05 Oct 2023 08:52 |
| DOI: | 10.1093/ofid/ofad020 |
| Open Access URL: | https://doi.org/10.1093/ofid/ofad020 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3173433 |
Dimensions
Dimensions
